| Literature DB >> 14713713 |
Luis Graca1, Alain Le Moine, Stephen P Cobbold, Herman Waldmann.
Abstract
A short-treatment with nondepleting antibodies, such as those targeting CD4 or CD154 (CD40 ligand), allows long-term graft survival without the need for continuous immunosuppression. This state of immune tolerance is maintained by regulatory CD4+ T cells present within both the lymphoid tissue and the tolerated graft. The nature of such regulatory T cells, their relationship to CD4+CD25+ T cells, and their mode of action have all been the subjects of much attention recently. Here, we review recent progress on understanding the nature, specificity, and mechanisms of action of T cells mediating dominant tolerance brought about by antibody therapy.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14713713 DOI: 10.1385/IR:28:3:181
Source DB: PubMed Journal: Immunol Res ISSN: 0257-277X Impact factor: 2.829